WallStreetZenWallStreetZen

NYSE: HAE
Haemonetics Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for HAE

Based on 7 analysts offering 12 month price targets for Haemonetics Corp

Min Forecast
$62.00+14.79%
Avg Forecast
$78.86+46%
Max Forecast
$99.00+83.3%

Should I buy or sell HAE stock?

Based on 7 analysts offering ratings for Haemonetics Corp.

Buy
Strong Buy
1 analysts 14.29%
Buy
3 analysts 42.86%
Hold
3 analysts 42.86%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although HAE's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates HAE as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their HAE stock forecasts and price targets.

HAE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-12
lockedlocked$00.00+00.00%2026-05-08
lockedlocked$00.00+00.00%2026-04-13
lockedlocked$00.00+00.00%2026-03-11
lockedlocked$00.00+00.00%2026-02-06
Baird
Top 20%
81
BuyMaintains$99.00+83.30%2025-12-15
JP Morgan
Bottom 28%
28
HoldMaintains$74.00+37.01%2025-12-12

1 of 1

Forecast return on equity

Is HAE forecast to generate an efficient return?

Company
35.43%
Industry
24.63%
Market
170.33%
HAE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HAE forecast to generate an efficient return on assets?

Company
12.96%
Industry
18.36%
HAE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HAE earnings per share forecast

What is HAE's earnings per share in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$5.34+46.41%
Avg 2 year Forecast
$5.98+63.73%
Avg 3 year Forecast
$6.95+90.38%
HAE's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

HAE revenue forecast

What is HAE's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$1.4B+6.81%
Avg 2 year Forecast
$1.5B+13.63%
Avg 3 year Forecast
$1.6B+18.56%
HAE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HAE earnings growth forecast

How is HAE forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
22.9%
Industry
26.26%
Market
34.27%
HAE's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
HAE's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
HAE's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

HAE revenue growth forecast

How is HAE forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
6.11%
Industry
9.92%
Market
13.98%
HAE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HAE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HAE vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
HAE$54.01$78.86+46.00%Buy
LMAT$97.22$117.00+20.35%Buy
XRAY$11.00$14.33+30.30%Hold
ICUI$123.23$163.50+32.68%Strong Buy
WRBY$26.95$29.00+7.61%Buy
View Top Medical Stocks

Haemonetics Stock Forecast FAQ

Is Haemonetics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NYSE: HAE) stock is to Buy HAE stock.

Out of 7 analysts, 1 (14.29%) are recommending HAE as a Strong Buy, 3 (42.86%) are recommending HAE as a Buy, 3 (42.86%) are recommending HAE as a Hold, 0 (0%) are recommending HAE as a Sell, and 0 (0%) are recommending HAE as a Strong Sell.

If you're new to stock investing, here's how to buy Haemonetics stock.

What is HAE's earnings growth forecast for 2027-2029?

(NYSE: HAE) Haemonetics's forecast annual earnings growth rate of 22.9% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 26.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.27%.

Haemonetics's earnings in 2026 is $175,436,000.On average, 12 Wall Street analysts forecast HAE's earnings for 2027 to be $248,342,894, with the lowest HAE earnings forecast at $232,719,227, and the highest HAE earnings forecast at $265,932,300. On average, 10 Wall Street analysts forecast HAE's earnings for 2028 to be $277,717,435, with the lowest HAE earnings forecast at $257,767,284, and the highest HAE earnings forecast at $297,258,637.

In 2029, HAE is forecast to generate $322,920,117 in earnings, with the lowest earnings forecast at $313,328,430 and the highest earnings forecast at $335,709,032.

What is HAE's revenue growth forecast for 2027-2029?

(NYSE: HAE) Haemonetics's forecast annual revenue growth rate of 6.11% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.98%.

Haemonetics's revenue in 2026 is $1,318,275,000.On average, 12 Wall Street analysts forecast HAE's revenue for 2027 to be $65,431,660,800, with the lowest HAE revenue forecast at $62,968,679,250, and the highest HAE revenue forecast at $68,824,069,350. On average, 9 Wall Street analysts forecast HAE's revenue for 2028 to be $69,614,082,300, with the lowest HAE revenue forecast at $66,035,788,350, and the highest HAE revenue forecast at $73,796,503,800.

In 2029, HAE is forecast to generate $72,634,720,050 in revenue, with the lowest revenue forecast at $70,450,566,600 and the highest revenue forecast at $75,515,943,750.

What is HAE's forecast return on assets (ROA) for 2027-2029?

(NYSE: HAE) forecast ROA is 12.96%, which is lower than the forecast US Medical Instruments & Supplies industry average of 18.36%.

What is HAE's Price Target?

According to 7 Wall Street analysts that have issued a 1 year HAE price target, the average HAE price target is $78.86, with the highest HAE stock price forecast at $99.00 and the lowest HAE stock price forecast at $62.00.

On average, Wall Street analysts predict that Haemonetics's share price could reach $78.86 by May 12, 2027. The average Haemonetics stock price prediction forecasts a potential upside of 46% from the current HAE share price of $54.01.

What is HAE's Earnings Per Share (EPS) forecast for 2027-2029?

(NYSE: HAE) Haemonetics's current Earnings Per Share (EPS) is $3.65. On average, analysts forecast that HAE's EPS will be $5.34 for 2027, with the lowest EPS forecast at $5.01, and the highest EPS forecast at $5.72. On average, analysts forecast that HAE's EPS will be $5.98 for 2028, with the lowest EPS forecast at $5.55, and the highest EPS forecast at $6.40. In 2029, HAE's EPS is forecast to hit $6.95 (min: $6.74, max: $7.22).

What is HAE's forecast return on equity (ROE) for 2027-2029?

(NYSE: HAE) forecast ROE is 35.43%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.